Latest Regulatory News

Mont Royal Resources has finalized its merger with Commerce Resources, creating a dual-listed critical metals company focused on advancing one of North America’s largest rare earth deposits in Québec. Backed by a fresh A$10 million capital raise and a seasoned leadership team, Mont Royal is poised to become a key player in the global rare earths market.

Acumentis delivered a 3.4% revenue increase to $58.1 million at its 2025 AGM, highlighting diversification and a positive outlook for FY26 amid easing inflation and expected rate cuts.

Restaurant Brands New Zealand advises shareholders to hold off on responding to Finaccess's takeover offer until the Target Company Statement is released, promising clearer guidance by late October.

MedAdvisor Solutions reported a steep 52.8% revenue decline in Q1 FY26, impacted by US regulatory pressures and vaccine program delays, while embarking on a strategic transformation to restore growth.

MedAdvisor reports a sharp 53% drop in 1Q FY26 revenue driven by U.S. regulatory and sector challenges, while advancing a major platform transformation and selling its ANZ business to emerge debt-free.

Arrow Minerals Limited has suspended all field activities in Guinea due to unresolved questions over exploration permit renewals, maintaining a cautious financial stance while awaiting government clarity.

Resolution Minerals is fast-tracking its downstream antimony strategy in Idaho, aiming to become a key US supplier while preparing for a Nasdaq listing with Tribeca Capital's support.

Element 25 has appointed Altris Engineering to lead the AU$64.8 million expansion of its Butcherbird manganese mine, a move that underpins its strategy to supply high-purity battery materials to the US electric vehicle market.

Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.

Apiam Animal Health Limited has entered a binding agreement with Adamantem Capital Fund II for a $228.4 million acquisition via a scheme of arrangement, offering shareholders a significant premium and flexible cash or scrip consideration options.

ACDC Metals reports compelling mineralogy results from its Goschen Central project, highlighting elevated rare earth element grades that reinforce its economic potential. The announcement coincides with strategic momentum from the Australia-US Critical Minerals Framework, positioning the project as a key player in global supply chains.

Island Pharmaceuticals secures FDA confirmation that regulatory feedback on Galidesivir’s approval pathway will arrive on schedule, underscoring the drug’s strategic importance amid US government disruptions.